Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Not long ago, some predicted that MannKind (NASDAQ: MNKD ) faced the serious risk of striking out on winning approval for Afrezza. Instead, those predictions swung and missed. The U.S. Food and Drug Administration recently approved the inhaled insulin.
With this regulatory hurdle out of the way, MannKind looks to be in the best position in the company's storied history. Nevertheless, some risks remain.
The most prominent risk that comes to mind is whether MannKind will secure a partner to commercialize Afrezza. My view is that this isn't really a question of "if," but rather of "when."
Granted, MannKind's management team has frequently stated over the past few years that discussions were under way with potential partners, but no deal was ever struck. I don't doubt that partners were interested -- just not enough to commit. That was then. MannKind now has an approved product in its back pocket.
http://www.fool.com/investing/general/2014/07/11/is-this-mannkinds-greatest-risk.aspx
With this regulatory hurdle out of the way, MannKind looks to be in the best position in the company's storied history. Nevertheless, some risks remain.
The most prominent risk that comes to mind is whether MannKind will secure a partner to commercialize Afrezza. My view is that this isn't really a question of "if," but rather of "when."
Granted, MannKind's management team has frequently stated over the past few years that discussions were under way with potential partners, but no deal was ever struck. I don't doubt that partners were interested -- just not enough to commit. That was then. MannKind now has an approved product in its back pocket.
http://www.fool.com/investing/general/2014/07/11/is-this-mannkinds-greatest-risk.aspx